All In Biotech

Drug Trial Radar · NCT05239468

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

72

Actual

Start

Mar 21, 2022

Primary completion

Sep 1, 2025

Study completion Sep 1, 2025

Sponsor

Lead sponsor
Intercept PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

Conditions

  • Primary Biliary Cholangitis

Interventions

  • Bezafibrate 100 mgDrug

    One tablet of bezafibrate 100 mg IR once daily

  • Bezafibrate 200 mgDrug

    Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR

  • Obeticholic Acid 5 mgDrug

    One tablet of obeticholic acid 5 mg tablet once daily.

  • Obeticholic Acid placeboDrug

    One tablet of obeticholic acid placebo tablet once daily

  • Bezafibrate PlaceboDrug

    One tablet of bezafibrate placebo tablet once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Alkaline Phosphatase (ALP)Time frame: Baseline to Week 12

Locations

26 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Southern California Gastrointestinal (GI) and Liver Centers (SCLC) - Coronado

    Coronado, California

  • Facey Medical Group

    Mission Hills, California

  • Schiff Center for Liver Diseases / University of Miami

    Miami, Florida

  • Tampa General Medical Group

    Tampa, Florida

  • Piedmont Atlanta Hospital

    Atlanta, Georgia

  • Loyola University Medical Center

    Maywood, Illinois

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Beth Israel Deaconess Medical Center Harvard Liver Research Center

    Boston, Massachusetts

  • NYU Langone Medical Center

    New York, New York

  • Wake Endoscopy Center

    Raleigh, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Gastro One

    Cordova, Tennessee

  • Gastrointestinal Associates of Northeast Tennessee

    Johnson City, Tennessee

  • Methodist Clinical Research Institute (CRI)

    Dallas, Texas

  • Houston Methodist Cancer Center

    Houston, Texas

  • American Research Corporation at the Texas Liver Institute

    San Antonio, Texas

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Hospital Universitario Austral

    Pilar, Argentina

  • Hospital Provincial del Centenario

    Rosario, Argentina

  • Hospital Italiano La Plata

    La Plata, Buenos Aires, Argentina

  • DIM Clinical Privada

    Ramos Mejía, Buenos Aires, Argentina

  • The Northern Alberta Clinical Trials and Research Centre

    Edmonton, Alberta, Canada

  • Pacific Gastroenterology Associates

    Vancouver, British Columbia, Canada

  • University of Montreal

    Montreal, Quebec, Canada

  • Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi

    Bologna, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.